Shandong Realcan Pharmaceutical Co Ltd Total Liabilities
Shandong Realcan Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Shandong Realcan Pharmaceutical Co Ltd (002589) has total liabilities worth CN¥10.10 Billion CNY (≈ $1.48 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Shandong Realcan Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
Total liabilities of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025. This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Shandong Realcan Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Shandong Realcan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Realcan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
China | CN¥788.71 Million |
|
Electronics Mart India Limited
NSE:EMIL
|
India | Rs21.71 Billion |
|
Guangzhou Boji Medical and Biotechnological Co Ltd
SHE:300404
|
China | CN¥569.21 Million |
|
Archean Chemical Industries Limited
NSE:ACI
|
India | Rs7.32 Billion |
|
Phenix Optical Co Ltd
SHG:600071
|
China | CN¥1.41 Billion |
|
Miracll Chemicals Co Ltd
SHE:300848
|
China | CN¥2.69 Billion |
|
Cancom SE
F:COK
|
Germany | €824.76 Million |
|
GFT Technologies SE
XETRA:GFT
|
Germany | €350.73 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Shandong Realcan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shandong Realcan Pharmaceutical Co Ltd assets under control.
Liquidity & Leverage Metrics
Shandong Realcan Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Shandong Realcan Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Realcan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual total liabilities of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥8.95 Billion ≈ $1.31 Billion |
-13.28% |
| 2024-12-31 | CN¥10.32 Billion ≈ $1.51 Billion |
-6.82% |
| 2023-12-31 | CN¥11.07 Billion ≈ $1.62 Billion |
-11.98% |
| 2022-12-31 | CN¥12.58 Billion ≈ $1.84 Billion |
-24.69% |
| 2021-12-31 | CN¥16.70 Billion ≈ $2.44 Billion |
-22.84% |
| 2020-12-31 | CN¥21.65 Billion ≈ $3.17 Billion |
-2.54% |
| 2019-12-31 | CN¥22.21 Billion ≈ $3.25 Billion |
-5.60% |
| 2018-12-31 | CN¥23.53 Billion ≈ $3.44 Billion |
+35.94% |
| 2017-12-31 | CN¥17.31 Billion ≈ $2.53 Billion |
+112.27% |
| 2016-12-31 | CN¥8.15 Billion ≈ $1.19 Billion |
+49.42% |
| 2015-12-31 | CN¥5.46 Billion ≈ $798.58 Million |
+41.64% |
| 2014-12-31 | CN¥3.85 Billion ≈ $563.82 Million |
+37.40% |
| 2013-12-31 | CN¥2.80 Billion ≈ $410.35 Million |
+27.24% |
| 2012-12-31 | CN¥2.20 Billion ≈ $322.51 Million |
+57.38% |
| 2011-12-31 | CN¥1.40 Billion ≈ $204.93 Million |
+18.34% |
| 2010-12-31 | CN¥1.18 Billion ≈ $173.18 Million |
+46.87% |
| 2009-12-31 | CN¥805.78 Million ≈ $117.91 Million |
+33.49% |
| 2008-12-31 | CN¥603.64 Million ≈ $88.33 Million |
-- |
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more